RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Health care utilization and costs among Medicaid-enrolled patients with schizophrenia experiencing multiple psychiatric relapses
Karve, S., Panish, JM., Dirani, RG., & Candrilli, S. (2012). Health care utilization and costs among Medicaid-enrolled patients with schizophrenia experiencing multiple psychiatric relapses. Health Outcomes Research in Medicine, 3(4), e183-e194. https://doi.org/10.1016/j.ehrm.2012.06.003
Objective<br>This study compared all-cause and schizophrenia-related health care utilization and costs among patients with schizophrenia using second-generation oral antipsychotics (SGOAs) and experiencing >=2 psychiatric-related relapses with those experiencing <2 relapses.<br><br>Study Design<br>Patients with schizophrenia who initiated SGOA therapy were identified in the MarketScan® Medicaid Multi-State database between July 1, 2004 and December 31, 2007. Patients were stratified by <2 psychiatric-related relapse events and >=2 psychiatric-related relapse events during the 12-month period following SGOA initiation. All-cause and schizophrenia-related health care utilization and costs were estimated for each cohort in various care settings. Univariate and multivariate regression analyses were conducted to assess the differences in all-cause and schizophrenia-related health care utilization and costs between the 2 cohorts. No adjustments were made for multiple inferential statistical tests.<br><br>Results<br>The cohort consisted of 19,813 patients, of whom 3714 (18.75%) had >=2 psychiatric-related relapse events during the follow-up period. On average, patients with >=2 psychiatric-related relapse events were younger than patients with <2 psychiatric-related relapse events (42.62 years vs. 44.21 years; P < 0.001), and the all-cause and schizophrenia-related inpatient costs were approximately 12 and 23 times higher, respectively. The mean covariate-adjusted predicted schizophrenia-related total medical costs per patient were significantly higher among patients with >=2 psychiatric-related relapse events than among patients with <2 psychiatric-related relapse events ($17,910 vs. $10,346; P < 0.001).<br><br>Conclusion<br>Patients who received an SGOA and experienced >=2 psychiatric-related relapse events within the first year of treatment incurred significantly greater all-cause and schizophrenia-related total medical costs than those with <2.